Rimas V. Lukas
Experienced in Histiocytosis

Dr. Rimas V. Lukas

Hematology Oncology | Neurology | Hematology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
23 Years of Experience
Experienced in Histiocytosis
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rimas Lukas is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Lukas has been practicing medicine for over 23 years and is rated as an Experienced provider by MediFind in the treatment of Histiocytosis. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Gastrostomy.

His clinical research consists of co-authoring 194 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Rush University Medical College, 2002
Residency
University of Chicago
Specialties
Hematology Oncology
Neurology
Hematology
Licenses
Psychiatry & Neurology in IL
Board Certifications
American Board Of Psychiatry And Neurology - Neurology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Medicine Mchenry
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

675 N St Clair St Ste 20-100, Galter Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Lukas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma
Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Drug, Device
Study Drug: Chemotherapy, Albumin-Bound Paclitaxel
Study Phase: Phase 1/Phase 2
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Drug, Radiation
Study Drugs: BMS-986205, Nivolumab, Temozolomide
Study Phase: Phase 1
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Enrollment Status: Terminated
Publish Date: June 06, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Memantine
Study Phase: Phase 3
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug, Biological
Study Drugs: Ad-RTS-hIL-12, Veledimex
Study Phase: Phase 1
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

194 Total Publications

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.
Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.
Journal: Research square
Published: October 03, 2025
Similar Doctors
Experienced in Histiocytosis
Dr. Irum Khan
Hematology | Oncology
Experienced in Histiocytosis
Dr. Irum Khan
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
22+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Irum Khan is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Khan has been practicing medicine for over 22 years and is rated as a Distinguished provider by MediFind in the treatment of Histiocytosis. Her top areas of expertise are Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Experienced in Histiocytosis
Dr. Edmund B. Paloyan
Oncology | Hematology Oncology | Hematology
Experienced in Histiocytosis
Dr. Edmund B. Paloyan
Oncology | Hematology Oncology | Hematology

Lakeland Medical Practices

3900 Hollywood Rd, 
Saint Joseph, MI 
 (60.2 miles away)
269-983-3368
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Edmund Paloyan is an Oncologist and a Hematologist Oncology provider in Saint Joseph, Michigan. Dr. Paloyan is rated as a Distinguished provider by MediFind in the treatment of Histiocytosis. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Breast Cancer, and Lynch Syndrome. Dr. Paloyan is currently accepting new patients.

Advanced in Histiocytosis
Dr. Sucha Nand
Hematology Oncology
Advanced in Histiocytosis
Dr. Sucha Nand
Hematology Oncology
2160 S First Ave, (luh - North Ent., Rm 7604), 
Maywood, IL 
 (11.7 miles away)
708-216-3304
Languages Spoken:
English
See accepted insurances

Sucha Nand is a Hematologist Oncology provider in Maywood, Illinois. Dr. Nand is rated as a Distinguished provider by MediFind in the treatment of Histiocytosis. His top areas of expertise are Thalassemia, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hemangioma Thrombocytopenia Syndrome, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lukas's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 20 Advanced Conditions
View All 83 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile